Gene therapy can provide cures for life-threatening diseases that do not respond well to other therapies and for acute conditions that rely on complex and expensive life-long medications. This presents a significant opportunity for companies to help people live better lives. The need for speed is paramount as many companies compete for the same indication.
Learn how our integrated approach can help you navigate the twist and turns of viral vector and gene therapy process development, tech transfer and all the way through to commercial readiness. This talk will shed light on topics relating to process development for viral vector manufacturing, analytics and commercial readiness.
Associate Director of Vaccines and Gene Therapy
Ratish Krishnan is a process development scientist by background and has a wealth of experience in vaccine, mAbs and gene therapy modalities from early discovery to late stage process validation and commercialization. He is passionate about providing solutions to bring treatments to market. He is a Biochemical Engineer by training and holds a Master’s degree in Biotechnology from Pennsylvania State University. Ratish has managed process development teams at Novartis and Pfizer for nearly a decade prior to his current role as an Associate Director of Vaccines and Gene Therapy for the Americas.